Trends in price, spending, and utilization of omalizumab among Medicare beneficiaries

Article Health Care Sciences & Services

Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022

Benjamin N. Rome et al.

Summary: This study simulated the drug selection and minimum savings that would have been achieved through drug price negotiation if implemented from 2018 to 2020. The results revealed the limitations of strict selection criteria and drugs becoming ineligible for negotiation during the time between selection and price implementation.

JAMA HEALTH FORUM (2023)

Add to Collection

Editorial Material Otorhinolaryngology

Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population

Vinay K. Rathi et al.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2022)

Add to Collection

Editorial Material Otorhinolaryngology

Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis

Lauren T. Roland et al.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2022)

Add to Collection

Editorial Material Otorhinolaryngology

Private payer-negotiated prices for FDA-approved biologic treatments for allergic diseases

Annette A. Wang et al.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps

George A. Scangas et al.

Summary: The study compared the cost-effectiveness of dupilumab and ESS in treating CRSwNP, with the results showing that the ESS treatment strategy is more cost-effective. Further research is needed to identify potential phenotypes or endotypes that will benefit most from dupilumab treatment in a cost-effective manner.

LARYNGOSCOPE (2021)

Add to Collection

Article Allergy

Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps

Anju T. Peters et al.

Summary: In this study, an indirect treatment comparison (ITC) was conducted to compare the efficacy of biologics plus INCS versus placebo among patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Results indicated that at week 24, dupilumab showed significantly greater improvements in key CRSwNP outcomes compared to omalizumab.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Allergy